Tower Research Capital (TRC)’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,678	Closed	-$11K	–	6506
2023 Q1	$11K	Buy	8,678 +2,093	+32%	+$3.42K	﹤0.01%	4305
2022 Q4	$11K	Buy	6,585 +937	+17%	+$1.19K	﹤0.01%	3923
2022 Q3	$10K	Sell	5,648 -2,099	-27%	-$6.26K	﹤0.01%	4609
2022 Q2	$23K	Buy	7,747 +6,354	+456%	+$38.8K	﹤0.01%	3676
2022 Q1	$10K	Buy	1,393 +1,112	+396%	+$10.9K	﹤0.01%	4394
2021 Q4	$5K	Buy	+281	New	+$3.27K	﹤0.01%	5234
2021 Q3	–	Sell	-100	Closed	-$1K	–	6352
2021 Q2	$1K	Buy	+100	New	+$1K	﹤0.01%	5302

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Tower Research Capital (TRC)'s PRDS Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2023, closing a stake of 8,678 shares — an estimated $11K sold.

Tower Research Capital (TRC) first reported a position in PRDS in Q2 2021 and held it in 7 quarters. The position peaked at $23K in Q2 2022. 59 funds tracked by Wall St. Rank hold PRDS as of Q2 2023.

Tower Research Capital (TRC) reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Tower Research Capital (TRC) sold 8,678 Pardes Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $11K.
Tower Research Capital (TRC) first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
Tower Research Capital (TRC)'s Pardes Biosciences, Inc. Common Stock position peaked at $23K in Q2 2022.
59 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.